Appendix C – Key reporting indicators
2020 rheumatic heart disease guidelines – key reporting indicators
| Diagnosis | Indicator | Data availability (yes/no) |
|---|---|---|
| ARF | Yearly ARF incidence by episode type, age group, sex and Ethnicit | Yes |
Yearly ARF recurrences
| Yes | |
| Rheumatic heart disease | Yearly RHD point prevalence by age group, sex, ethnicity, severity | Yes |
| Secondary prophylaxis | Proportion of people receiving secondary prophylaxis each year
| Yes |
Source: RHDAustralia (ARF/RHD writing group) 2020
Potential indicators from the RHD Endgame Strategy
| Diagnosis | Indicator | Data availability (yes/no) |
|---|---|---|
| Primary prevention | Proportion of sore throat and skin sore infections in children assessed and treated by a trained healthcare professional. | No |
| ARF | Number and rate of new cases of (definite) ARF notified per time period – by age and sex, Indigenous category, region of onset. | Yes |
| Proportion of ARF episodes which are recurrence. | Yes | |
| Number and proportion of patients with ARF recurrence. | Yes | |
| Number of deaths recorded with ARF as a cause (either underlying cause or associated cause of death) | No | |
| RHD | Number and rate of incident cases of RHD, by age and sex, Indigenous category, valve involved. Severity of RHD at time of diagnosis. | Yes, except valve involvement. |
| What proportion of people with mild RHD remain mild over 12-month period. | No | |
| Secondary prophylaxis | Number of people indicated to receive secondary prophylaxis by age, sex and Indigenous category. Proportion of patients who received 100%, >80%, 50-79%, and less than 40% of doses in 12-month period. | Yes |
| Intervention | Provision of echos to Priority 1,2 and 3 as per current Australian Guideline | No |
| Mortality | Number of maternal deaths coded (or attributed, or coronial investigations) associated with RHD. | No |
| Number of deaths recorded with RHD as a cause, underlying cause or associated cause of death. | No |
Source: Wyber, Noonan & et.al 2020
RHDAustralia (ARF/RHD writing group) (2020) The 2020 Australian guideline for the prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease, 3.2 edn (2022), RHDAustralia, Menzies School of Health Research, Darwin.
Wyber R, Noonan K, Halkon C, Enkel S, Ralph A, Bowen A, Cannon J, Haynes E, Mitchell A, Bessarab D, Katzenellenbogen J, Seth R, Bond-Smith D, Currie B, McAullay D, D’Antoine H, Steer A, de Klerk N, Krause V, Snelling T, Trust S, Slade R, Colquhoun S, Reid C, Brown A, Carapetis J (2020), The RHD Endgame Strategy: The blueprint to eliminate rheumatic heart disease in Australia by 2031, The END RHD Centre of Research Excellence, Telethon Kids Institute, accessed 21 February 2024.